Oruka Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 14, 2024, by Oruka Therapeutics, Inc. (formerly ARCA biopharma, Inc.). The filing addresses the retroactive adjustment of audited financial statements following the consummation of a business combination on August 29, 2024, and a subsequent 1-for-12 reverse stock split effective September 3, 2024.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. The document serves to disclose the filing of retroactively adjusted audited financial statements as of February 6, 2024, rather than reporting new operational financial results.
Material Changes
- Business Combination: The Company completed a merger with Pre-Merger Oruka on August 29, 2024.
- Capital Structure Adjustment: A 1-for-12 reverse stock split was effected on September 3, 2024.
- Exchange Ratio: Pre-Merger Oruka common stock and pre-funded warrants were converted into Company Common Stock at an exchange ratio of 6.8569 shares.
- Financial Statement Adjustment: Audited financial statements as of February 6, 2024, have been retroactively adjusted to reflect the reverse stock split and exchange ratio.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the merger and stock split mechanics. No unusual items or contingencies are described in this specific report.
Investor Verification Checklist
- Verify the details of the retroactively adjusted audited financial statements filed as Exhibit 99.1.
- Confirm the impact of the 1-for-12 reverse stock split on share ownership and trading on The Nasdaq Global Market under symbol ORKA.
- Review the Merger Agreement dated April 3, 2024, for terms regarding the exchange ratio and conversion of pre-funded warrants.